Wealth Tribune

Tuesday, September 10, 2024
Tuesday, September 10, 2024
All Right Reserved. Designed and Developed by PenciDesign
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Home Headlines Novo Nordisk to begin 2024 share buybacks

Novo Nordisk to begin 2024 share buybacks

by Uma
0 comments
2024 02 06T074923Z 2 LYNXMPEK1507I RTROPTP 4 NOVO NORDISK RESULTS WEGOVY STRATEGY

Novo Nordisk to begin 2024 share buybacks

OSLO (Reuters) – Novo Nordisk will on Tuesday begin the execution of its planned share buyback programme for 2024, the Danish maker of obesity drug Wegovy and diabetes treatment Ozempic said in a statement.

Novo on Jan. 31 said it planned to carry out a share repurchase plan of up to 20 billion Danish crowns ($2.88 billion) to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes.

The company completed its previous 12-month share repurchase programme on Jan. 30.

($1 = 6.9337 Danish crowns)

 

(Reporting by Terje Solsvik, editing by Anna Ringstrom and Essi Lehto)

 

Recent Post